{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:44:12Z","timestamp":1785757452624,"version":"3.56.0"},"reference-count":150,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polsky Urologic Cancer Institute at Northwestern University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>KMT2A-rearranged (MLL-r) leukemias are highly aggressive hematological malignancies that require improved targeted therapies. DOT1L (histone H3K79 methyltransferase) functions as a critical oncogenic driver and represents an important therapeutic target in these high-risk leukemias. However, clinical responses to the first-in-class DOT1L inhibitor pinometostat (EPZ5676) have been modest, attributed to suboptimal pharmacokinetics and, more fundamentally, to the recognition that DOT1L possesses methyltransferase-independent functions that evade catalytic inhibition. This highlights the need for strategies that abrogate the full spectrum of DOT1L activity to effectively treat these high-risk leukemias. Proteolysis-targeting chimeras (PROTACs), which induce selective degradation of the DOT1L protein rather than inhibiting its catalytic activity, have therefore emerged as a promising approach. Notably, VHL-recruiting DOT1L PROTACs, such as DOT1L808, have demonstrated improved pharmacokinetic profiles and potent antileukemic activity in preclinical in vivo models. However, these findings remain preclinical, and significant challenges including oral bioavailability, potential toxicity, and lack of clinical validation must be addressed before clinical translation. In this review, we provide an overview of the evolving understanding of the biology of DOT1L, discuss existing MLL small molecule therapies, and evaluate current advances in therapeutically targeting DOT1L, with particular focus on the targeted degradation of DOT1L as a promising therapeutic strategy for high-risk KMT2A-r leukemia.<\/jats:p>","DOI":"10.3390\/cells15151399","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:24:07Z","timestamp":1785752647000},"page":"1399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting DOT1L Epigenetic Moonlighting in MLL-Rearranged Leukemia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-7585","authenticated-orcid":false,"given":"Dikshat Gopal","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Urology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1233","authenticated-orcid":false,"given":"Ahmad Hasan","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Urology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2087-516X","authenticated-orcid":false,"given":"Uzer Abdulaziz","family":"Memon","sequence":"additional","affiliation":[{"name":"NHL Municipal Medical College, Ahmedabad 380006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-5051","authenticated-orcid":false,"given":"Gary E.","family":"Schiltz","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Northwestern University, Evanston, IL 60208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarki A.","family":"Abdulkadir","sequence":"additional","affiliation":[{"name":"Department of Urology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","article-title":"Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: The MD Anderson experience","volume":"5","author":"Kantarjian","year":"2021","journal-title":"Blood Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41467-023-36370-x","article-title":"Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia","volume":"14","author":"Kamens","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"BSR20200514","DOI":"10.1042\/BSR20200514","article-title":"Identification of co-expressed genes associated with MLL rearrangement in pediatric acute lymphoblastic leukemia","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Winters, A.C., and Bernt, K.M. (2017). MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00004"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chan, A.K.N., and Chen, C.W. (2019). Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00081"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.7150\/thno.56737","article-title":"Small-molecule inhibitor of AF9\/ENL-DOT1L\/AF4\/AFF4 interactions suppresses malignant gene expression and tumor growth","volume":"11","author":"Wu","year":"2021","journal-title":"Theranostics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.chembiol.2023.05.007","article-title":"New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation","volume":"30","author":"Arwood","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40291-025-00775-9","article-title":"Bridging the Gap: Cost-Effective Strategies for Detecting Ph-Like B-Lineage ALL in Resource-Limited Settings","volume":"29","author":"Gupta","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/leu.2013.135","article-title":"The MLL recombinome of acute leukemias in 2013","volume":"27","author":"Meyer","year":"2013","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11899-020-00582-5","article-title":"MLL-Rearranged Acute Lymphoblastic Leukemia","volume":"15","author":"Keng","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc2915","article-title":"Licensed to elongate: A molecular mechanism for MLL-based leukaemogenesis","volume":"10","author":"Mohan","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/leu.2009.33","article-title":"New insights to the MLL recombinome of acute leukemias","volume":"23","author":"Meyer","year":"2009","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/onc.2016.488","article-title":"MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia","volume":"36","author":"Prange","year":"2017","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood.2021015036","article-title":"Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia","volume":"140","author":"Tirtakusuma","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2012.23","article-title":"Newly diagnosed acute lymphoblastic leukemia in China (II): Prognosis related to genetic abnormalities in a series of 1091 cases","volume":"26","author":"Mi","year":"2012","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: A report from the Children\u2019s Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-021-00504-5","article-title":"Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center","volume":"11","author":"Chen","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-021-01057-7","article-title":"Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.35051","article-title":"A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia","volume":"130","author":"Gupta","year":"2024","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/10428194.2021.1999439","article-title":"PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients","volume":"63","author":"Gupta","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.34665","article-title":"Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: A report of Indian patients","volume":"129","author":"Gupta","year":"2023","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.galenos.2021.2021.0326","article-title":"Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients","volume":"39","author":"Gupta","year":"2022","journal-title":"Turk. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cncr.34957","article-title":"Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India","volume":"129","author":"Gupta","year":"2023","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41416-023-02294-y","article-title":"Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting","volume":"129","author":"Gupta","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1101\/gad.1898410","article-title":"Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)","volume":"24","author":"Mohan","year":"2010","journal-title":"Genes Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27365","DOI":"10.1073\/pnas.2001075117","article-title":"DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation","volume":"117","author":"Cao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/15592294.2019.1699991","article-title":"DOT1L: A key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment","volume":"15","author":"Sarno","year":"2020","journal-title":"Epigenetics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-022-01258-8","article-title":"A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105247","DOI":"10.1016\/j.exphem.2025.105247","article-title":"KMT2A-rearranged leukemia: From mechanism to drug development","volume":"151","author":"Ernst","year":"2025","journal-title":"Exp. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1073\/pnas.0510347103","article-title":"The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1007\/s00432-023-04752-9","article-title":"Targeting the undruggable: Menin inhibitors ante portas","volume":"149","author":"Dempke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41594-023-01087-4","article-title":"CRISPR\u2013ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia","volume":"30","author":"Gilan","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1097-2765(04)00081-4","article-title":"Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus","volume":"13","author":"Hughes","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1073\/pnas.0408836102","article-title":"Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors","volume":"102","author":"Milne","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","article-title":"A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1","volume":"23","author":"Numata","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","article-title":"Menin critically links MLL proteins with LEDGF on cancer-associated target genes","volume":"14","author":"Yokoyama","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1101\/gad.2015411","article-title":"The super elongation complex (SEC) and MLL in development and disease","volume":"25","author":"Smith","year":"2011","journal-title":"Genes Dev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cantilena, S., AlAmeri, M., Che, N., Williams, O., and de Boer, J. (2024). Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor. Cancers, 16.","DOI":"10.3390\/cancers16234017"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Yokoyama, A. (2018). RNA Polymerase II-Dependent Transcription Initiated by Selectivity Factor 1: A Central Mechanism Used by MLL Fusion Proteins in Leukemic Transformation. Front. Genet., 9.","DOI":"10.3389\/fgene.2018.00722"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.celrep.2016.03.018","article-title":"Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes","volume":"15","author":"Buttner","year":"2016","journal-title":"Cell Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.exphem.2015.05.012","article-title":"Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond","volume":"43","author":"Chen","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eadg6593","DOI":"10.1126\/sciadv.adg6593","article-title":"Epigenetic moonlighting: Catalytic-independent functions of histone modifiers in regulating transcription","volume":"9","author":"Morgan","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"194548","DOI":"10.1016\/j.bbagrm.2020.194548","article-title":"The molecular functions of common and atypical MLL fusion protein complexes","volume":"1863","author":"Takahashi","year":"2020","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Guarnera, L., D\u2019Addona, M., Bravo-Perez, C., and Visconte, V. (2024). KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169023"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/fmc.13.214","article-title":"Challenges and opportunities in targeting the menin-MLL interaction","volume":"6","author":"Cierpicki","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","article-title":"AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia","volume":"37","author":"Lin","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccr.2009.12.040","article-title":"A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription","volume":"17","author":"Yokoyama","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-020-18013-7","article-title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer","volume":"11","author":"Vatapalli","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.18632\/oncotarget.5860","article-title":"DOT1L: A new therapeutic target for aggressive breast cancer","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"eaav5590","DOI":"10.1126\/sciadv.aav5590","article-title":"Inhibition of histone methyltransferase DOT1L silences ERalpha gene and blocks proliferation of antiestrogen-resistant breast cancer cells","volume":"5","author":"Nassa","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41588-025-02289-w","article-title":"ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L","volume":"57","author":"Feng","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5045\/br.2020.2020255","article-title":"Changing the frequency and spectra of chromosomal aberrations in Korean patients with acute leukemia in a tertiary care hospital","volume":"55","author":"Park","year":"2020","journal-title":"Blood Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Liu, W., Deng, L., Song, Y., and Redell, M. (2014). DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098270"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2020006113","article-title":"Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts","volume":"136","author":"Perner","year":"2020","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.V124.21.387.387","article-title":"The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed\/Refractory Patients with MLL-Rearranged Leukemia","volume":"124","author":"Stein","year":"2014","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/acs.jmedchem.0c01111","article-title":"Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders","volume":"63","author":"Shen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2106148118","DOI":"10.1073\/pnas.2106148118","article-title":"DOT1L complex regulates transcriptional initiation in human erythroleukemic cells","volume":"118","author":"Wu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbpa.2019.11.012","article-title":"Targeted protein degradation: Current and future challenges","volume":"56","author":"Hanzl","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cbpa.2017.05.016","article-title":"Targeted protein knockdown using small molecule degraders","volume":"39","author":"Raina","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1021\/acs.jmedchem.5c03128","article-title":"Development of DOT1L-Targeted Protein Degraders for Treating MLL-r Leukemia","volume":"69","author":"Quan","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"117595","DOI":"10.1016\/j.ejmech.2025.117595","article-title":"Discovery of the first-in-class DOT1L PROTAC degrader","volume":"291","author":"Yim","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","article-title":"Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase","volume":"112","author":"Min","year":"2003","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0960-9822(02)00901-6","article-title":"Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain","volume":"12","author":"Feng","year":"2002","journal-title":"Curr. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/genetics\/150.2.613","article-title":"Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae","volume":"150","author":"Singer","year":"1998","journal-title":"Genetics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/B978-0-12-823928-5.00020-7","article-title":"Chapter 31\u2014Histone methylation modifiers in medical therapeutics","volume":"29","author":"Trojer","year":"2021","journal-title":"Med. Epigenet. (Second Ed.)"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molcel.2011.03.006","article-title":"Dot1 and histone H3K79 methylation in natural telomeric and HM silencing","volume":"42","author":"Takahashi","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"30421","DOI":"10.1074\/jbc.C200366200","article-title":"Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase","volume":"277","author":"Lacoste","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1101\/gad.1001502","article-title":"Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association","volume":"16","author":"Ng","year":"2002","journal-title":"Genes Dev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0092-8674(02)00759-6","article-title":"Dot1p modulates silencing in yeast by methylation of the nucleosome core","volume":"109","author":"Gafken","year":"2002","journal-title":"Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1182\/blood-2010-12-327668","article-title":"Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation","volume":"117","author":"Jo","year":"2011","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1038\/ncomms15889","article-title":"DOT1L safeguards cartilage homeostasis and protects against osteoarthritis","volume":"8","author":"Monteagudo","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature10953","article-title":"Chromatin-modifying enzymes as modulators of reprogramming","volume":"483","author":"Onder","year":"2012","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Malcom, C.A., Piaseka-Srader, J., Chakravarthi, V.P., Borosha, S., Ratri, A., Alvarez, N., Vivian, J.L., Fields, T.A., Rumi, M.K., and Fields, P.E. (2020). The Role of DOT1L Methyltransferase Activity in Fetal Hematopoiesis. bioRxiv.","DOI":"10.1101\/2020.09.30.319889"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cc.28104","article-title":"The histone methyltransferase Dot1\/DOT1L as a critical regulator of the cell cycle","volume":"13","author":"Kim","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Wood, K., Tellier, M., and Murphy, S. (2018). DOT1L and H3K79 Methylation in Transcription and Genomic Stability. Biomolecules, 8.","DOI":"10.3390\/biom8010011"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/OTT.S145971","article-title":"Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy","volume":"11","author":"Castelli","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0968-0004(01)01856-4","article-title":"Chromatin silencing protein and pachytene checkpoint regulator Dot1p has a methyltransferase fold","volume":"26","author":"Dlakic","year":"2001","journal-title":"Trends Biochem. Sci."},{"key":"ref_97","unstructured":"wwPDB Consortium (2018). Protein Data Bank: The single global archive for 3D macromolecular structure data. Nucleic Acids Res., 47, D520\u2013D528."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2012.327","article-title":"Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","article-title":"H3K79 methylation profiles define murine and human MLL-AF4 leukemias","volume":"14","author":"Krivtsov","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Malcom, C.A., Ratri, A., Piasecka-Srader, J., Borosha, S., Chakravarthi, V.P., Alvarez, N.S., Vivian, J.L., Fields, T.A., Karim Rumi, M.A., and Fields, P.E. (2021). Primitive Erythropoiesis in the Mouse is Independent of DOT1L Methyltransferase Activity. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.813503"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8970","DOI":"10.1093\/nar\/gkad640","article-title":"Dot1l cooperates with Npm1 to repress endogenous retrovirus MERVL in embryonic stem cells","volume":"51","author":"Zhao","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_102","first-page":"11251","article-title":"Dot1 promotes H2B ubiquitination by a methyltransferase-independent mechanism","volume":"46","author":"Korthout","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-017-02759-8","article-title":"Dot1 regulates nucleosome dynamics by its inherent histone chaperone activity in yeast","volume":"9","author":"Lee","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G.A., Kadam, S., Zhai, H., and Valdez, R. (2008). The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet., 4.","DOI":"10.1371\/journal.pgen.1000190"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ncomms2304","article-title":"Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors","volume":"3","author":"Yu","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13318-017-0404-3","article-title":"Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L","volume":"42","author":"Waters","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1021\/acsmedchemlett.9b00452","article-title":"New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse","volume":"10","author":"Stauffer","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acs.jcim.5b00738","article-title":"Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays","volume":"56","author":"Chen","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"116072","DOI":"10.1016\/j.bmc.2021.116072","article-title":"Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity","volume":"35","author":"Jang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/acschembio.8b00933","article-title":"Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor","volume":"14","author":"Chen","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"112023","DOI":"10.1016\/j.ejmech.2019.112023","article-title":"Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library","volume":"189","author":"Gibbons","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1021\/acs.jmedchem.1c02228","article-title":"Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides","volume":"65","author":"Khirsariya","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.bmc.2018.02.020","article-title":"Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay","volume":"26","author":"Song","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/acsmedchemlett.6b00167","article-title":"Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach","volume":"7","author":"Chen","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1002\/chem.201600259","article-title":"In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors","volume":"22","author":"Zhu","year":"2016","journal-title":"Chemistry"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/acs.jmedchem.6b01785","article-title":"Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.114.214577","article-title":"DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells","volume":"350","author":"Klaus","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: From molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Grigsby, S.M., Friedman, A., Chase, J., Waas, B., Ropa, J., Serio, J., Shen, C., Muntean, A.G., Maillard, I., and Nikolovska-Coleska, Z. (2021). Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis. Cancers, 13.","DOI":"10.3390\/cancers13040642"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-026-00760-w","article-title":"Targeting epigenetic methylation: Emerging diagnosis and therapeutic strategies in cancer","volume":"15","author":"Zhu","year":"2026","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-031-62731-6_18","article-title":"HOXA9 Regulome and Pharmacological Interventions in Leukemia","volume":"1459","author":"Aryal","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40164-023-00445-8","article-title":"Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia","volume":"12","author":"Schneider","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nsmb.3249","article-title":"Functional interdependence of BRD4 and DOT1L in MLL leukemia","volume":"23","author":"Gilan","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4062\/biomolther.2025.075","article-title":"DOT1L as a Therapeutic Target: Insights into Epigenetic Regulation and Cancer Treatment","volume":"33","author":"Choi","year":"2025","journal-title":"Biomol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"114290","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"114838","DOI":"10.1016\/j.ejmech.2022.114838","article-title":"A bibliometric analysis of PROTAC from 2001 to 2021","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: A novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_134","first-page":"100413","article-title":"Targeted protein degradation in cancers: Orthodox PROTACs and beyond","volume":"4","author":"Li","year":"2023","journal-title":"Innovation"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: Elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","article-title":"BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes","volume":"23","author":"Ma","year":"2022","journal-title":"Cancer Biol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13072-022-00461-8","article-title":"Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity","volume":"15","author":"Dreijerink","year":"2022","journal-title":"Epigenet. Chromatin"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e935","DOI":"10.1097\/HS9.0000000000000935","article-title":"The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML","volume":"7","author":"Rasouli","year":"2023","journal-title":"Hemasphere"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition","volume":"13","author":"Perner","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e70132","DOI":"10.1002\/cncr.70132","article-title":"Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment","volume":"131","author":"Anaya","year":"2025","journal-title":"Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: Advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1039\/D3SC02361C","article-title":"Opportunities and challenges of protein-based targeted protein degradation","volume":"14","author":"Shen","year":"2023","journal-title":"Chem. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"118499","DOI":"10.1016\/j.ejmech.2025.118499","article-title":"Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs","volume":"305","author":"Hu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Rej, R.K., Allu, S.R., Roy, J., Acharyya, R.K., Kiran, I.N.C., Addepalli, Y., and Dhamodharan, V. (2024). Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040494"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"103917","DOI":"10.1016\/j.drudis.2024.103917","article-title":"Exploring the chemical space of orally bioavailable PROTACs","volume":"29","author":"Apprato","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e70258","DOI":"10.1002\/mco2.70258","article-title":"Advancing Design Strategy of PROTACs for Cancer Therapy","volume":"6","author":"Luo","year":"2025","journal-title":"MedComm"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Chen, X., Zhou, J., Dong, X., Xu, Y., and Chen, B. (2025). Regulatory role of E3 ubiquitin ligases in multiple myeloma: From molecular mechanisms to therapeutic strategies. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1620097"},{"key":"ref_150","first-page":"100032","article-title":"E3 ubiquitin ligases in neurodegenerative diseases","volume":"13","author":"Hou","year":"2026","journal-title":"Mil. Med. Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:44:43Z","timestamp":1785753883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":150,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151399"],"URL":"https:\/\/doi.org\/10.3390\/cells15151399","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}